Form 8-K - Current report:
SEC Accession No. 0001493152-25-018269
Filing Date
2025-10-16
Accepted
2025-10-16 09:20:26
Documents
20
Period of Report
2025-10-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 61907
2 EX-5.1 ex5-1.htm EX-5.1 132947
3 EX-10.1 ex10-1.htm EX-10.1 289078
4 EX-10.2 ex10-2.htm EX-10.2 103236
5 EX-10.3 ex10-3.htm EX-10.3 114112
6 EX-10.4 ex10-4.htm EX-10.4 114116
7 EX-10.5 ex10-5.htm EX-10.5 115862
8 GRAPHIC ex5-1_001.jpg GRAPHIC 5654
  Complete submission text file 0001493152-25-018269.txt   1336670

Data Files

Seq Description Document Type Size
9 XBRL SCHEMA FILE aktx-20251014.xsd EX-101.SCH 3849
10 XBRL DEFINITION FILE aktx-20251014_def.xml EX-101.DEF 26710
11 XBRL LABEL FILE aktx-20251014_lab.xml EX-101.LAB 36826
12 XBRL PRESENTATION FILE aktx-20251014_pre.xml EX-101.PRE 25334
22 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5742
Mailing Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210
Business Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210 (646) 350-0702
Akari Therapeutics Plc (Filer) CIK: 0001541157 (see all company filings)

EIN.: 981034922 | State of Incorp.: X0
Type: 8-K | Act: 34 | File No.: 001-36288 | Film No.: 251396617
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)